Treatment options for hepatitis delta virus infection

Current Infectious Disease Reports

Volumn 15, Issue 1, 2013, Pages 31-38

  Heidrich, Benjamin ^a   Manns, Michael P ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

HBV; HDV; HDV therapy; Hepatitis B; Hepatitis delta

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HEPATITIS DELTA ANTIGEN; INTERFERON; LAMIVUDINE; MYRCLUDEX B; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PRENYLATION INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; END STAGE LIVER DISEASE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; NONHUMAN; PROTEIN PRENYLATION; SEROCONVERSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS CARRIER; VIRUS ENTRY; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84873082268     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0307-z     Document Type: Article

References (67)

1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011.
2. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31-40.
3. Arboleda M, Castilho MC, Fonseca JC, Albuquerque BC, Saboia RC, et al. Epidemiological aspects of hepatitis B and D virus infection in the northern region of Amazonas, Brazil. Trans R Soc Trop Med Hyg. 1995;89:481-3.
4. Gaeta GB, Stroffolini T, Smedile A, Niro G, Mele A. Hepatitis delta in Europe: vanishing or refreshing? Hepatology. 2007;46:1312-3.
5. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection-not a vanishing disease in Europe! Hepatology. 2007;45:1331-2. author reply 1332-1333.
6. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, et al. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009;16:883-94.
7. Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008;80:277-82.
8. Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845-52.
9. Farci P. Delta hepatitis: an update. J Hepatol. 2003;39 Suppl 1:S212-9.
10. Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology. 2000;32:824-7.
11. Taylor JM. Hepatitis delta virus. Virology. 2006;344:71-6.
12. Weiner AJ, Choo QL, Wang KS, Govindarajan S, Redeker AG, et al. A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol. 1988;62:594-9.
13. Lai MM. RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus. J Virol. 2005;79:7951-8.
14. Greco-Stewart VS, Schissel E, Pelchat M. The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III. Virology. 2009;386:12-5.
15. Radjef N, Gordien E, Ivaniushina V, Gault E, Anais P, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004;78:2537-44.
16. Makuwa M, Caron M, Souquiere S, Malonga-Mouelet G, Mahe A, et al. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol. 2008;46:754-6.
17. Shakil AO, Hadziyannis S, Hoofnagle JH, Di Bisceglie AM, Gerin JL, et al. Geographic distribution and genetic variability of hepatitis delta virus genotype I. Virology. 1997;234:160-7.
18. Parana R, Kay A, Molinet F, Viana S, Silva LK, et al. HDV genotypes in the Western Brazilian Amazon region: a preliminary report. AmJTrop Med Hyg. 2006;75:475-9.
19. Wu JC, Chiang TY, Sheen IJ. Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis. J Gen Virol. 1998;79(Pt 5):1105-13.
20. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130:1625-35.
21. Niro GA, Casey JL, Gravinese E, Garrubba M, Conoscitore P, et al. Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol. 1999;30:564-9.
22. Manock SR, Kelley PM, Hyams KC, Douce R, Smalligan RD, et al. An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador. AmJTrop Med Hyg. 2000;63:209-13.
23. Flodgren E, Bengtsson S, Knutsson M, Strebkova EA, Kidd AH, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol. 2000;38:3311-6.
24. Heidrich B, Beatriz SC, Idilman R, Kabacam G, Bremer B, et al. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int. 2012;32:1415-25.
25. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53:834-40.
26. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629-38.
27. Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18:434-42.
28. Calle-Serrano B, Grosshennig A, Heidrich B, Jaroszewicz J, Kirschner J, et al. Comparing the long-term outcome of hepatitis delta and HBV monoinfection: Is HDV-infection really worse? J Hepatol. 2011;54:144.
29. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:790-2.
30. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol. 2009;90:2759-67.
31. Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol. 2011;85:432-9.
32. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 52: 658-64.
33. Wedemeyer H. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol. 2010;52:627-9.
34. Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis Delta antigen persistence after liver transplantation. J Hepatol. 2011.
35. Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol. 2010;48:2022-9.
36. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19:221-40.
37. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2010;30:430-7.
38. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, et al. Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol. 2007;45:525-74.
39. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50: 227-42. The guideline clearly describes the clinical management of patients infected with HBV as well as patients coinfected with HBV and HDV.
40. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:88-94.
41. Rosina F, Saracco G, Lattore V, Quartarone V, Rizzetto M, et al. Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis. Prog Clin Biol Res. 1987;234:299-303.
42. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322-31. This the so far largest clinical trial treating patients chronically infected with HDV with pegylated Interferon. Overall, the SVR rate was 25-30 %.
43. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728-35.
44. Lamers MH, Kirgiz OO, Heidrich B, Wedemeyer H, Drenth JP. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012;17:1029-37.
45. Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;28:494-8.
46. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740-9.
47. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10:721-6.
48. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999;117:1229-33.
49. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005;22:227-32.
50. Yurdaydin C, Bozkaya H, Gurel S, Tillmann HL, Aslan N, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002;37:266-71.
51. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314-21.
52. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713-20.
53. Kabacam G, Onder FO, Yakut M, Seven G, Karatayli SC, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. 2012;55:645-50.
54. Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther. 2011;16:915-24.
55. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13:97-102.
56. Martin-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73-9.
57. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73-85.
58. Serrano BC, Manns MP, Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis. 2012;32:120-9.
59. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
60. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348-56.
61. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2012.
62. Vietheer PT, Netter HJ, Sozzi T, Bartholomeusz A. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol. 2005;79:6570-3.
63. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology. 1995;21:333-9.
64. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest. 2003;112:407-14.
65. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008;26:335-41.
66. Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685-94.
67. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822-32.